Merus (MRUS) Aandeel Koers
Merus Koers
De omzet is de afgelopen 11 jaar met 45,6% per jaar gegroeid tot 34,88 Miljoen USD. De nettowinstmarge van Merus ligt op -595,9% en is ten opzichte van -285,6% enkele jaren eerder gedaald. Analisten hanteren een mediaan koersdoel van 98,94 USD — dat impliceert 9,9% boven de huidige koers. Van de 23 analisten geven 9 het aandeel een koopadvies — per saldo een Houden-consensus.
Merus aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Merus bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Merus
The business model of Merus NV focuses on developing innovative bispecific antibody therapeutics to treat various types of cancer. By utilizing its proprietary technology platform, Merus aims to design and develop bispecific antibodies that can simultaneously target and bind to multiple cancer cell targets. This unique approach has the potential to enhance the efficacy and safety profile of cancer treatments. Merus collaborates with pharmaceutical companies to advance its pipeline candidates, while also retaining rights to develop and commercialize certain product candidates. Through its research and development efforts, Merus NV strives to provide groundbreaking solutions for patients suffering from cancer-related diseases.
Merus NV is primarily active in the biotechnology industry.
The main competitors of Merus NV in the market include biotechnology companies such as Regeneron Pharmaceuticals, Inc., Amgen Inc., Genmab A/S, and Roche Holding AG. These companies operate in similar therapeutic areas, developing innovative antibody-based therapeutics and immuno-oncology treatments, potentially competing with Merus NV's pipeline. It is important for investors and market participants to closely monitor the competitive landscape as it can impact Merus NV's market share, product development, and financial performance.
Merus NV is a biotechnology company based in the Netherlands. Founded in 2003, the company specializes in developing innovative bispecific antibody therapeutics for the treatment of cancer. Merus NV has a unique approach to target tumor cells directly while minimizing side effects. The company has a strong pipeline of candidates, including MCLA-128, MCLA-117, and MCLA-158, targeting various types of cancers. With collaborations and partnerships with renowned pharmaceutical companies, Merus NV aims to advance the field of antibody therapeutics and make a lasting impact on patient care. Throughout its history, Merus NV has achieved significant milestones in drug discovery and clinical development, positioning itself as a key player in the biotechnology industry.
Merus NV, a leading biotechnology company, has achieved several significant milestones. The company successfully initiated multiple clinical trials, including ongoing studies for its innovative bispecific antibody programs. Merus NV also secured strategic collaborations with renowned pharmaceutical companies, further validating its cutting-edge technology and expanding its market reach. In addition, Merus NV has received regulatory approvals for its investigational therapies, paving the way for potential commercialization. These achievements demonstrate the company's strong commitment to advancing its pipeline and driving growth. Merus NV's dedication to scientific excellence and continuous innovation positions it as a formidable player in the biotech industry.
Merus NV is primarily present in the Netherlands and the United States.
Merus NV represents values such as innovation, collaboration, and patient-centricity. With a commitment to advancing bispecific antibody therapeutics, Merus NV aims to improve patient outcomes and address unmet medical needs. The company's corporate philosophy is based on fostering scientific excellence and leveraging its core technologies to develop transformative medicines. Merus NV embraces a culture of integrity, diversity, and teamwork, driving its pursuit of novel solutions in the field of oncology. By integrating its unique approach with strategic partnerships, Merus NV strives to deliver breakthrough treatments for patients.
Analisten hanteren momenteel een gemiddeld koersdoel van 99,48 USD voor het aandeel Merus (mediaan: 98,94 USD), oftewel +10,5 % ten opzichte van de laatste koers. De consensus is gebaseerd op 23 analistenratings.
23 analisten beoordelen het aandeel Merus momenteel: 9 adviseren kopen, 14 houden en 0 verkopen. Voor 2026 verwachten analisten dat Merus een omzet van 49,33 Miljoen USD en winst per aandeel van -5,44 USD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel Merus op 81,31 EUR (90,00 USD).
Het aandeel Merus (MRUS) is genoteerd aan 3 beurzen, waaronder: NASDAQ (MRUS), Frankfurt (2GH.F), München (2GH.MU).
Merus NV is a biotechnology company specializing in the development of bispecific antibodies for the treatment of cancer. The company's business model is based on the research, development, and commercialization of novel therapies to combat cancer. Merus NV has three main business areas and develops products in each of these categories: therapeutic products, diagnostics, and research. The company's therapeutic products utilize bispecific antibodies (Biclonics®) that combine the properties of two different antibodies, resulting in greater specificity, higher efficacy, and reduced toxicity. Merus NV is building a pipeline of bispecific antibodies targeting a variety of cancer types. Currently, the company has three products in clinical development: MeMo, MCLA-128, and MCLA-117. Merus NV collaborates closely with renowned pharmaceutical companies such as Incyte and DSM Biomedical in the development of cancer immunotherapies. In the diagnostics product line, Merus NV offers a technology platform that enables the development of diagnostic tests for therapeutic products and supports biomarker research. The company is also involved in the development of antibody imaging tools, serving an important role in toxic analysis and biomarker-driven clinical studies. Finally, Merus NV's research department supports its own development activities as well as those of external parties through collaborations and alliances. In summary, Merus NV's business model is based on the development, commercialization, and marketing of bispecific antibodies to combat cancer. With innovative solutions and technologies in the field of diagnostic tests and therapy monitoring, the company has distinct competitive advantages and can meet the demands of customers and partners. Merus NV is a leading company in the field of bispecific antibody technology and offers a diverse product pipeline to meet the demanding requirements of the entire cancer market.
De verwachte omzet van Merus bedraagt 49,33 Miljoen USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van Merus bedraagt -374,11 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Merus bedraagt momenteel -16,56. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Merus-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Merus bedraagt momenteel 125,58. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Merus-aandeel.
De Eulerpool Kwaliteitsscore voor Merus is 6/10.
De ISIN van Merus is NL0011606264. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Merus is A2AKFX. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Merus is MRUS. Onder dit beurstickersymbool wordt het Merus-aandeel op de beurs verhandeld.
Merus aandeel
Merus Peer Group
Merus Ticker
Merus FIGI
Alle fundamentals en diepgaande analyse van Merus
Onze aandelenanalyse van het Merus-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Merus. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: